Profile data is unavailable for this security.
About the company
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality. The Company's advanced synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR) a kinase that plays a critical role in DNA damage response (DDR). ATR and Checkpoint Kinase 1 are critical DDR kinases that prevent the collapse of replication forks into DNA double-strand breaks. It has completed all IND enabling studies for its oral, small molecule WEE1 inhibitor, APR-1051, and received United States Food and Drug Administration (FDA) clearance of its IND. It has an early-stage program that is in the lead optimization stage, for an undisclosed DDR target. The Company is evaluating potential combination opportunities within its pipeline, including research on the combination of ATRN-119 and APR-1051 that is supported by a Phase II SBIR grant from the National Cancer Institute.
- Revenue in USD (TTM)963.81k
- Net income in USD-12.72m
- Incorporated2019
- Employees7.00
- LocationAprea Therapeutics Inc3805 OLD EASTON ROADDOYLESTOWN 18902United StatesUSA
- Phone+1 (617) 463-9385
- Fax+1 (302) 655-5049
- Websitehttps://www.aprea.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nymox Pharmaceutical Corp | 0.00 | -4.87m | 24.25m | 3.00 | -- | -- | -- | -- | -0.0536 | -0.0536 | 0.00 | -0.0204 | 0.00 | -- | -- | -- | -255.75 | -264.40 | -- | -464.48 | -- | -- | -- | -13,001.67 | -- | -42.44 | -- | -- | -- | -- | 47.55 | -- | -- | -- |
| SAB Biotherapeutics Inc | 2.60m | -39.87m | 24.37m | 57.00 | -- | 0.4613 | -- | 9.36 | -6.26 | -6.26 | 0.396 | 5.72 | 0.0456 | -- | 5.44 | 45,657.37 | -69.91 | -- | -86.60 | -- | -- | -- | -1,531.84 | -- | -- | -- | 0.0762 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| Lisata Therapeutics Inc | 0.00 | -20.05m | 24.42m | 25.00 | -- | 0.568 | -- | -- | -2.46 | -2.46 | 0.00 | 5.18 | 0.00 | -- | -- | 0.00 | -35.01 | -45.97 | -38.40 | -50.47 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.57 | -- | -- | -- |
| Iterum Therapeutics PLC | 0.00 | -35.58m | 24.83m | 14.00 | -- | -- | -- | -- | -2.64 | -2.64 | 0.00 | -0.3734 | 0.00 | -- | -- | 0.00 | -91.54 | -118.12 | -136.45 | -199.23 | -- | -- | -- | -890,554.10 | -- | -- | 1.44 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| TherapeuticsMD Inc | 1.20m | -6.20m | 25.60m | 1.00 | -- | 0.8931 | -- | 21.35 | -0.58 | -0.6955 | 0.1103 | 2.49 | 0.0236 | -- | 0.4556 | 1,199,000.00 | -12.19 | -53.35 | -16.34 | -111.61 | 73.89 | 86.67 | -516.93 | -236.57 | -- | -- | 0.00 | -- | -98.14 | -39.53 | -816.85 | -- | -- | -- |
| Medicine Man Technologies Inc | 172.45m | -42.70m | 25.61m | 729.00 | -- | 0.2821 | -- | 0.1485 | -1.60 | -1.60 | 3.01 | 1.61 | 0.5064 | 3.99 | 39.49 | 236,553.90 | -10.15 | -8.33 | -11.95 | -9.85 | 44.08 | 45.57 | -20.03 | -15.71 | 0.5027 | 0.3143 | 0.5679 | -- | 8.20 | 78.78 | -62.56 | -- | 200.89 | -- |
| Acasti Pharma Inc | 0.00 | -38.77m | 25.65m | 32.00 | -- | 0.3966 | -- | -- | -5.06 | -5.06 | 0.00 | 6.88 | 0.00 | -- | -- | -- | -40.18 | -45.71 | -41.30 | -50.84 | -- | -- | -- | -69,798.47 | -- | -14.38 | 0.00 | -- | -- | -- | -332.11 | -- | -45.53 | -- |
| Aprea Therapeutics Inc | 963.81k | -12.72m | 25.90m | 7.00 | -- | 0.8955 | -- | 26.87 | -3.32 | -3.32 | 0.2503 | 5.57 | 0.0296 | -- | -- | 137,687.10 | -39.00 | -68.66 | -43.83 | -77.19 | -- | -- | -1,319.45 | -42,112.84 | -- | -- | 0.00 | -- | -- | -- | 87.32 | -- | 90.61 | -- |
| Unity Biotechnology Inc | 0.00 | -34.78m | 26.02m | 19.00 | -- | 1.08 | -- | -- | -2.33 | -2.33 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -40.18 | -47.21 | -48.47 | -53.51 | -- | -- | -- | -6,395.92 | -- | -- | 0.00 | -- | -100.00 | -- | 10.36 | -- | -61.28 | -- |
| Singular Genomics Systems Inc | 2.49m | -96.21m | 27.02m | 255.00 | -- | 0.1724 | -- | 10.85 | -1.31 | -1.31 | 0.034 | 2.12 | 0.0091 | 0.233 | 32.98 | 9,764.71 | -35.33 | -- | -37.29 | -- | -41.49 | -- | -3,863.90 | -- | 9.54 | -- | 0.0614 | -- | 280.52 | -- | -4.34 | -- | -- | -- |
| Alterola Biotech Inc | 0.00 | -2.88m | 27.17m | 1.00 | -- | -- | -- | -- | -0.0027 | -0.0027 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -47.24 | -- | -63.88 | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -- | -- | 73.07 | -- | -- | -- |
| Aptorum Group Ltd | 431.38k | -2.82m | 27.25m | 3.00 | -- | 1.04 | -- | 63.16 | -0.9126 | -0.9126 | 0.0954 | 4.80 | 0.0208 | 30.36 | 3.88 | 143,793.30 | -20.92 | -40.45 | -19.62 | -42.36 | 2.45 | -4.04 | -1,006.30 | -1,233.68 | 1.18 | -- | 0.1694 | -- | -66.71 | 2.38 | 71.18 | -- | -78.15 | -- |
| Oncternal Therapeutics Inc | 1.15m | -36.38m | 27.26m | 27.00 | -- | 1.19 | -- | 23.68 | -12.35 | -12.35 | 0.3907 | 7.75 | 0.0263 | -- | -- | 42,629.63 | -83.23 | -49.40 | -95.97 | -54.51 | -- | -- | -3,160.73 | -1,342.98 | -- | -- | 0.00 | -- | -47.32 | -- | 10.62 | -- | -- | -- |
| Viracta Therapeutics Inc | 0.00 | -47.99m | 27.49m | 40.00 | -- | 4.88 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2821 | 0.00 | -- | -- | 0.00 | -75.51 | -86.35 | -112.64 | -106.38 | -- | -- | -- | -11,853.94 | -- | -84.18 | 0.6277 | -- | -- | -- | -3.78 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -8.05m | 27.78m | 8.00 | -- | 11.07 | -- | -- | -0.7249 | -0.7249 | 0.00 | 0.1048 | 0.00 | -- | -- | 0.00 | -172.23 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Aprea Therapeutics Inc's reporting currency: US Dollar USD
29.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AIGH Capital Management LLCas of 31 Mar 2024 | 539.30k | 9.93% |
| Sio Capital Management LLCas of 31 Mar 2024 | 276.60k | 5.09% |
| Sphera Funds Management Ltd.as of 31 Mar 2024 | 270.00k | 4.97% |
| Nantahala Capital Management LLCas of 31 Mar 2024 | 205.76k | 3.79% |
| DAFNA Capital Management LLCas of 31 Mar 2024 | 137.17k | 2.53% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 115.98k | 2.14% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 26.74k | 0.49% |
| Geode Capital Management LLCas of 31 Mar 2024 | 20.22k | 0.37% |
| HighTower Advisors LLCas of 31 Mar 2024 | 13.86k | 0.26% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 8.43k | 0.16% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
